Thailand Inflation Remains Negative for 10th Straight Month in January 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
